Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04258462 · ClinicalTrials.gov registry record · Phase 2
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
A Phase 2 study of Renal Cell Cancer and Kidney Neoplasm, sponsored by Zhen Wang, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT04258462 is a Phase 2 study of Renal Cell Cancer and Kidney Neoplasm that is active but no longer recruiting, run by Zhen Wang, MD. The registered enrollment target is 54 participants, below the 121-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04258462, a Phase 2 study of Renal Cell Cancer and Kidney Neoplasm, is active but no longer recruiting, sponsored by Zhen Wang, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagnostic imaging of tumors. Hyperpolarized 13C pyruvate MRI may help doctors determine non-invasively whether a kidney tumor is a benign tumor or cancer, and if cancer, how aggressive it is. This may help doctors and participants with renal tumors in the future to make better treatment decisions.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- DRUG Hyperpolarized Carbon C 13 Pyruvate
- DRUG Hyperpolarized 13C,15N2-urea
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04258462
The ClinicalTrials.gov registry entry for NCT04258462 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Zhen Wang, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Renal Cell Cancer appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT04258462 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04258462 about?
NCT04258462 is a clinical study titled "Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors". This feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagnostic imaging of tum...
What is the current status of trial NCT04258462?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2019-01-15. Estimated completion is 2026-10-31.
What conditions does trial NCT04258462 study?
This clinical trial studies the following conditions: Renal Cell Cancer, Kidney Neoplasm, Benign Kidney Neoplasm.
What interventions are being tested in trial NCT04258462?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (DRUG), Hyperpolarized 13C,15N2-urea (DRUG).
Who is sponsoring clinical trial NCT04258462?
This trial is sponsored by Zhen Wang, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04258462 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
COMPLETED · Phase 2
-
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
COMPLETED · Phase 2
-
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
COMPLETED · Phase 2
-
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.